FORUM 4
Organised by DG Research & Innovation, European Commission
Future developments and their implications for Europe
Identifying tomorrow's challenges and opportunities to health allows for investing in the right public health research now in Europe and getting prepared for the future:
What will be the main health challenges to be addressed in 2050?
Which external factors will influence these developments, e.g. demographic changes, climate change, lifestyle? '
Which scientific and technological developments will shape the future?
How to get prepared to address these problems? What is the role of public health research?
How to structure and prioritize public health research in Europe to face up to these challenges?
This session will first discuss which scientific and technological developments, in the medical field, are likely to shape the way health care is provided. It will then analyse the impact of changes in demand and supply for health services and discuss the implications for public health research in Europe. Each presentation will be followed by questions from the panel and the audience.
Short summary of the first day's discussion by the Chair
TIA Sørensen, Professor of Metabolic Epidemiology , University of Copenhagen, Denmark
What can the pharmaceutical industry deliver in 2050?
P Keil, Head Global Public Policy, Novartis, Switzerland
ICT in health care by 2050
D Kalra, Professor, UCL Centre for Health Informatics and Multiprofessional Education, UK
What will our health systems look like in 2050?
H Kluge, Director, Division of Health Systems and Public Health, WHO Regional Office for Europe
Discussion with chair, the panellists, speakers and audience
R Madelin, Director General, DG CONNECT, European Commission
P Lange, former Director General, Life Sciences Research for Health, Berlin, Germany
K Lamiraud, Associate Professor, Department of Economics, ESSEC Business School, France
M Wysocki, Director, National Institute of Public Health, Poland
M Kosinska, Secretary General, European Public Health Alliance
A Olauson, Chairman, AGRENSKA, Sweden
SG Scintee, Deputy General Director, National School of Public Health Management and Professional Development, Romania
Closing remarks
L Matthiessen, Head of Unit Infectious Diseases and Public Health, DG RTD, European Commission